U.S. Markets
Regenerpon's (REGN) Dupixent (dupilumab) approved in the US as the first and only medicine for Allergic Fungal Rhinosinusitis
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
